Cticseattle.com - develops biopharmaceuticals for cancer treatments
Title
Cell Therapeutics Cancer Research, Cancer Therapies, and Cancer Drug Development Home Page
Description
A Commitment to More Effective Cancer Treatments and Cancer Drugs
As CTI's cancer drugs progress through clinical trials to commercialization, our commitment to patients and the real issues of their cancer treatments grows stronger. The challenge to overcome the therapeutic limitations of cancer treatment provides us with a focus and sense of urgency.
Targeting the Side Effects and Toxicities of Conventional Cancer Therapies
Today, more than 9.2 million Americans have cancer, and one in three people in North America and Europe will develop cancer at some point in their lifetime. At the time of diagnosis, 70 percent of patients have tumors that have already spread to other parts of their body. So, almost all receive systemic therapy such as chemotherapy during the course of their disease.
Despite recent advances in sequencing the human genome and the introduction of new biologic therapies for the treatment of cancer, almost all patients with advanced cancer will receive chemotherapy at some point during the treatment of their disease. Four classes of chemotherapy agents — anthracyclines, camptothecins, platinates, and taxanes — account for more than 95% of all chemotherapy cancer drug usage. Unfortunately, there are significant limitations and complications associated with these agents that result in a high rate of treatment failure. The principal limitations of chemotherapy in treating cancer include:
